Immune-mediated Red Cell Destruction
Immune-mediated Blood Cell Destruction
Destruction of red blood cells is caused by the presence of antibodies to the proteins on the surface of circulating red cells. These antibodies can be caused by an immune response to previously transfused red cells, an autoimmune response against one’s own red cells, or caused by a rare interaction of various drugs and a patient’s red cells. Once an antibody has been formed, a patient may need to receive red blood cell products that are negative for the antigen in question.
Versiti’s Immunohematology Reference Laboratory provides compatible blood to patients with unique transfusion needs.
Our labs have earned a reputation for solving complex serological transfusion problems. We specialize in evaluation of autoimmune, DAT negative, drug-induced hemolytic anemia and the provision of specialty matched red cell products. Each year, we receive samples from across the country for detection of drug-dependent red cell antibodies and Super Coombs testing.
Our laboratories are supported in these activities by their stock of rare reagents, skill, special techniques, and high level of training and expertise. As an active participant in the American Rare Donor Program (ARDP), we maintain a large inventory of rare blood at our four locations.
Versiti physicians and lab professionals have more than 50 years of experience helping blood banks and clinicians solve their most difficult transfusion medicine problems. We understand your challenges and have designed our red blood cell genotyping services to help you meet those challenges every day.
Versiti delivers results faster and more cost effectively than other labs. More importantly, we also provide you with confidence in your results and patient care. Our red blood cell genotyping services will help you:
- Improve transfusion patient care
- Reduce red cell alloimmunization
- Enhance red cell utilization
- Potentially reduce donor base screening costs
Versiti’s donor red blood cell genotyping helps you build a well-characterized donor pool so you can meet the transfusion needs of future patients. Our service covers common and rare antigens, including those found in patients with sickle cell disease and thalassemia. Compared to serological antigen typing, Versiti’s high-throughput approach provides cost savings and supports patient care.
Versiti’s donor screening service will help you:
- Potentially reduce donor RBC antigen screening costs
- Quickly identify antigen-negative units
- Provide excellent patient care
Versiti’s patient red blood cell (RBC) genotyping panel provides you with the accuracy and confidence to ensure the highest quality of transfusion patient care. Our genotyping service allows you to characterize the alleles associated with clinically significant blood group antigens before or during treatment. These panels are especially beneficial for patients presenting with warm autoantibodies, positive DATs and those who have been recently transfused.
Our panels fulfill all the requirements needed in today’s transfusion medicine:
- Clinically significant antigens
- Rapid turnaround time of less than 72 hours
- Market-sensitive pricing
Versiti is a pioneer in prenatal red blood cell genotyping. We began offering this testing in 1995 and have more than 25 years of experience in hemolytic disease of the newborn. Our physicians are always available to consult on high-risk pregnancy management, including intrauterine transfusions.
Versiti’s prenatal red blood cell genotyping services include:
- Single antigen system testing
- Case-based evaluations of mother, father and fetus
- Antigen-negative and CMV-negative red cell products for intrauterine transfusions